ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)

7 March 2019

Immutep receives A$872,351 R&D Tax Incentive

SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$872,351 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2018 fiscal year, mainly related to the Company’s TACTI-mel trial, a Phase I clinical study in melanoma using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.

Immutep will apply the funding towards furthering its current active clinical trial programs for its lead product, IMP321.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase Ib clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial referred to as TACTI-002 (Two ACTive Immunotherapies) to evaluate a combination of efti with KEYTRUDA® (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a planned Phase I clinical trial referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinical.trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869).

Further information can be found on the Company’s website [www.immutep.com](http://www.immutep.com) or by contacting:

**U.S. Investors:**
Jay Campbell, Chief Business Officer, Immutep Limited
+1 (917) 860-9404; [jay.campbell@immutep.com](mailto:jay.campbell@immutep.com)

**Australian Investors/Media:**
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; [mgregorowski@citadelmagnus.com](mailto:mgregorowski@citadelmagnus.com)

**U.S. Media:**
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; [garth@lifesciadvisors.com](mailto:garth@lifesciadvisors.com)